These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30846172)

  • 41. Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer.
    Verma V; Allen PK; Simone CB; Gay HA; Lin SH
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1383-1391. PubMed ID: 29118230
    [No Abstract]   [Full Text] [Related]  

  • 42. Prognostic value of phosphorylated Raf kinase inhibitory protein at serine 153 and its predictive effect on the clinical response to radiotherapy in nasopharyngeal carcinoma.
    Li S; Liu T; Mo W; Hou Q; Zhou Y; Liu M; He Z; Liu Z; Chen Q; Wang H; Guo X; Xia W; Zeng M; Zhao H
    Radiat Oncol; 2016 Sep; 11(1):121. PubMed ID: 27647315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design of a prognostic score model for nasopharyngeal carcinoma.
    Luo XL; He W; Huang H; Chen QY; Liang Y; Mai HQ; Huang HQ; Cai QQ
    Head Neck; 2015 May; 37(5):624-9. PubMed ID: 24599631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma.
    Wan XB; Wei L; Li H; Dong M; Lin Q; Ma XK; Huang PY; Wen JY; Li X; Chen J; Ruan DY; Lin ZX; Chen ZH; Liu Q; Wu XY; Hong MH
    Eur J Cancer; 2013 Jul; 49(10):2356-64. PubMed ID: 23541571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
    Peng L; Chen YP; Xu C; Tang LL; Chen L; Lin AH; Liu X; Sun Y; Ma J
    Oral Oncol; 2018 Nov; 86():258-265. PubMed ID: 30409310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival without adjuvant chemotherapy for selected patients with stage II and III nasopharyngeal carcinoma after concurrent chemoradiotherapy alone.
    Wu JS; Tsai YC; Jian JJ; Chen HH; Horng CF; Cheng SH
    Head Neck; 2018 Sep; 40(9):2070-2077. PubMed ID: 29756398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Five-year survival and median survival time of nasopharyngeal carcinoma in Hospital Universiti Sains Malaysia.
    Siti-Azrin AH; Norsa'adah B; Naing NN
    Asian Pac J Cancer Prev; 2014; 15(15):6455-9. PubMed ID: 25124642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.
    Shen L; Li W; Wang S; Xie G; Zeng Q; Chen C; Shi F; Zhang Y; Wu M; Shu W; Pan C; Xia Y; Wu P
    Radiology; 2016 Sep; 280(3):805-14. PubMed ID: 27023116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis.
    Blanchard P; Lee A; Marguet S; Leclercq J; Ng WT; Ma J; Chan AT; Huang PY; Benhamou E; Zhu G; Chua DT; Chen Y; Mai HQ; Kwong DL; Cheah SL; Moon J; Tung Y; Chi KH; Fountzilas G; Zhang L; Hui EP; Lu TX; Bourhis J; Pignon JP;
    Lancet Oncol; 2015 Jun; 16(6):645-55. PubMed ID: 25957714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.
    Lee AW; Tung SY; Ngan RK; Chappell R; Chua DT; Lu TX; Siu L; Tan T; Chan LK; Ng WT; Leung TW; Fu YT; Au GK; Zhao C; O'Sullivan B; Tan EH; Lau WH
    Eur J Cancer; 2011 Mar; 47(5):656-66. PubMed ID: 21112774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort.
    Al-Husseini MJ; Saad AM; Turk T; Tabash MA; Abdel-Rahman O
    J Gastrointest Cancer; 2019 Dec; 50(4):794-800. PubMed ID: 30105523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prior cancer history predicts the worse survival of patients with nasopharyngeal carcinoma.
    Yeh CF; Chin YC; Huang WH; Lan MY
    Eur Arch Otorhinolaryngol; 2022 Nov; 279(11):5381-5387. PubMed ID: 35731292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of prior cancer on non-small cell lung cancer trial eligibility.
    Herman M; Liu Z; Shepherd FA; Leighl N; Liu G; Bradbury PA
    Cancer Med; 2021 Jul; 10(14):4814-4822. PubMed ID: 34145985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HPV status in patients with nasopharyngeal carcinoma in the United States: A SEER database study.
    Wotman M; Oh EJ; Ahn S; Kraus D; Costantino P; Tham T
    Am J Otolaryngol; 2019; 40(5):705-710. PubMed ID: 31277887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone Metastases Pattern in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Real-World Analysis in the SEER Database.
    Yang X; Ren H; Yu W; Li H; Yang X; Fu J
    Biomed Res Int; 2020; 2020():2098325. PubMed ID: 32724795
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Refining the Role of Lymph Node Biopsy in Survival for Patients with Nasopharyngeal Carcinoma: Population-Based Study from the Surveillance Epidemiology and End-Results Registry.
    Lv JW; Zhou GQ; Chen YP; Tang LL; Mao YP; Chen L; Li WF; Lin AH; Ma J; Sun Y
    Ann Surg Oncol; 2017 Sep; 24(9):2580-2587. PubMed ID: 28681157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of facility volume on patient treatments and survival outcomes in nasopharyngeal carcinoma.
    Goshtasbi K; Abiri A; Lehrich BM; Haidar YM; Tjoa T; Kuan EC
    Head Neck; 2021 Sep; 43(9):2755-2763. PubMed ID: 33998094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal management of oligometastatic nasopharyngeal carcinoma.
    Liu H; Yang P; Jia Y
    Eur Arch Otorhinolaryngol; 2022 Feb; 279(2):567-576. PubMed ID: 34089384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period.
    Huang H; Yao Y; Deng X; Weng H; Chen Z; Yu L; Wang Z; Fang X; Hong H; Huang H; Lin T
    Front Immunol; 2023; 14():1195659. PubMed ID: 37622113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.